Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 4129-4129 ◽  
Author(s):  
Hanno Riess ◽  
Jean-Luc Van Laethem ◽  
Uwe Marc Martens ◽  
Volker Heinemann ◽  
Patrick Michl ◽  
...  
2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e14542-e14542
Author(s):  
A. R. He ◽  
J. J. Hwang ◽  
J. Marshall ◽  
M. Pishvaian ◽  
R. Slack ◽  
...  

2004 ◽  
Vol 28 (8-9) ◽  
pp. 645-650 ◽  
Author(s):  
Thierry André ◽  
Monique Noirclerc ◽  
Pascal Hammel ◽  
Roderich Meckenstock ◽  
Bruno Landi ◽  
...  

2016 ◽  
Vol 114 (7) ◽  
pp. 737-743 ◽  
Author(s):  
Stacey M Stein ◽  
Edward S James ◽  
Yanhong Deng ◽  
Xiangyu Cong ◽  
Jeremy S Kortmansky ◽  
...  

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e15226-e15226 ◽  
Author(s):  
Edward Samuel James ◽  
Xiaopan Yao ◽  
Xiangyu Cong ◽  
Jia Li ◽  
Carol Hahn ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document